COVID-19 Vaccines: AstraZeneca’s UK Study Not Good Enough For US FDA Authorization, Slaoui Says

Operation Warp Speed chief scientific advisor confirms doubts about the Phase III data from two UK and Brazil studies; says efficacy results in US trials of AstraZeneca and Janssen vaccines expected by mid-January.

Dartboard on a tree background.the arrows miss target.
Results from the UK and Brazil trials of AstraZeneca's vaccine likely missed the US FDA's mark for an EUA. • Source: Shutterstock

Data from AstraZeneca PLC and Oxford University’s non-US Phase III trials of their COVID-19 vaccine candidate will not be good enough to support an emergency use authorization by the US Food and Drug Administration, Operation Warp Speed’s Moncef Slaoui predicts.

Slaoui is chief scientific advisor to OWS, and while he does not represent the FDA his view is likely to...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet